Spontaneous ocular autoimmunity in mice expressing a transgenic T Cell receptor specific to retina: A tool to dissect mechanisms of uveitis

Current Molecular Medicine

Volumn 15, Issue 6, 2015, Pages 511-516

  Horai, R ^a   Chong, W P ^a   Zhou, R ^a   Chen, J ^a,b   Silver, P B ^a   Agarwal, R K ^a   Caspi, R R ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Animal model; Autoimmunity; EAU; Th1; Th17; Uveitis

Indexed keywords

CYTOKINE; RETINOL BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; EYE PROTEIN; INTERSTITIAL RETINOL-BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; EYE INFLAMMATION; GENE DOSAGE; GENE EXPRESSION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; RETINA; TH1 CELL; TH17 CELL; UVEITIS; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; EYE PROTEINS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RETINA; RETINOL-BINDING PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH17 CELLS; UVEITIS;

EID: 84940935601     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150731095201     Document Type: Article

References (15)

1. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004; 218(4): 223-36.
2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111(3): 491-500; discussion.
3. Caspi RR. A look at autoimmunity and inflammation in the eye. J Clin Invest 2010; 120(9): 3073-83.
4. Yang Y, Xiao X, Li F, Du L, Kijlstra A, Yang P. Increased IL-7 expression in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2012; 53(2): 1012-7.
5. Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49(7): 3058-64.
6. Mattapallil MJ, Silver PB, Mattapallil JJ, et al. Uveitisassociated epitopes of retinal antigens are pathogenic in the humanized mouse model of uveitis and identify autoaggressive T cells. J Immunol 2011; 187(4): 1977-85.
7. Karabekian Z, Lytton SD, Silver PB, Sergeev YV, Schneck JP, Caspi RR. Antigen/MHC class II/Ig dimers for study of uveitogenic T cells: IRBP p161-180 presented by both IA and IE molecules. Invest Ophthalmol Vis Sci 2005; 46(10): 3769- 76.
8. Horai R, Silver PB, Chen J, et al. Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen. J Autoimmun 2013; 44: 21-33.
9. Horai R, Zárate-Bladés CR, Dillenburg-Pilla P, et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity 2015; (in press).
10. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006; 7(4): 354-9.
11. Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ. Influence of donor and histocompatibility factors on corneal graft outcome. Transplantation 1994; 58(11): 1210-6.
12. Zhou R, Horai R, Silver PB, et al. The living eye "disarms" uncommitted autoreactive T cells by converting them to Foxp3(+) regulatory cells following local antigen recognition. J Immunol 2012; 188(4): 1742-50.
13. Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205(4): 799-810.
14. Tang J, Zhu W, Silver PB, Su SB, Chan CC, Caspi RR. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol 2007; 178(9): 5578- 87.
15. Chong WP, Horai R, Mattapallil MJ, et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun 2014; 50: 12-22.